Retinal imaging in Alzheimer’s disease

Carol Y Cheung,1 Vincent Mok,2 Paul J Foster,3 Emanuele Trucco,4 Christopher Chen5,6 Tien Yin Wong7,8

ABSTRACT
Identifying biomarkers of Alzheimer’s disease (AD) will accelerate the understanding of its pathophysiology, facilitate screening and risk stratification, and aid in developing new therapies. Developments in non-invasive retinal imaging technologies, including optical coherence tomography (OCT), OCT angiography and digital retinal photography, have provided a means to study neuronal and vascular structures in the retina in people with AD. Both qualitative and quantitative measurements from these retinal imaging technologies (e.g., thinning of peripapillary retinal nerve fibre layer, inner retinal layer, and choroidal layer, reduced capillary density, abnormal vasodilatory response) have been shown to be associated with cognitive function impairment and risk of AD. The development of computer algorithms for respective retinal imaging methods has further enhanced the potential of retinal imaging as a viable tool for rapid, early detection and screening of AD. In this review, we present an update of current retinal imaging techniques and their potential applications in AD research. We also discuss the newer retinal imaging techniques and future directions in this expanding field.

INTRODUCTION
Alzheimer’s disease (AD), the most common form of dementia, is a major public health and clinical challenge globally.1 Despite decades in research, the pathophysiology of AD remains unclear. The current thinking is that the neuropathology of AD, as characterised by accumulation of misfolded amyloid-β and tau protein, begins years before the onset of clinical symptoms. Given this long natural history, there are opportunities for early disease detection and thus timely intervention.2 Indeed, recent clinical trials have suggested the efficacy of certain measures (e.g., lifestyle interventions or medication) in improving symptoms or slowing progression of AD.3

The definition of AD has also evolved in the past decade with the discovery of novel in vivo biomarkers for AD.4,5 It has been shown that clinically diagnosed cases of dementia presumably due to AD may be amyloid-negative in up to 25% of cases.7 Thus, biomarker confirmation has been proposed to improve the precision of AD diagnosis and now even biomarkers are indispensable for an AD diagnosis.8,9 The evolution in definition and diagnostic criteria of AD and other dementias may account for some of the variations and differences seen between studies discussed in this review. The 2018 National Institute on Aging and Alzheimer’s Association Research Framework defines AD in vivo by abnormal biomarkers of cerebral amyloid-β deposition and pathologic tau and treats cognitive impairment as a symptom or sign of the disease.9 This implies the cognitive function of a person affected by AD can thus range from cognitively unimpaired (preclinical AD) to mild cognitive impairment (MCI) (AD MCI), to dementia (AD dementia).10 Although this latest framework encourages in vivo detection and study of AD at an earlier stage (e.g., preclinical AD or AD MCI), current technologies to detect amyloid-β and tau pathology using positron emission tomography (PET) brain imaging or cerebrospinal fluid (CSF) examination are limited due to their high cost, technical complexity, invasiveness of the procedures and/or the necessity of using radioactive tracers. Thus, identifying alternative, more accessible technologies and biomarkers of preclinical AD prior to onset of cognitive impairment may accelerate the understanding of the pathogenesis of AD, facilitate screening and stratification of risk, and ultimately aid in the discovery, development and testing of new treatments or preventive therapies in clinical trials.10

The retina, a neurosensory layered tissue lining the back of the eye and directly connected to the brain via the optic nerve, receives light that the lens has focused, converts the light into neural signals and sends these signals on to the brain for visual recognition. The retina has long been considered a ‘platform’ to study disorders in the central nervous system (CNS), as it is an accessible extension of the brain in terms of embryology, anatomy and physiology (box 1).11 Figure 1 shows the optic nerve head, macular area, nerve fibre layer, arterioles and venules captured from a retinal photograph. Similar to the neurovascular unit (NVU) in the CNS, the retinal NVU contains neurons (ganglion cells, amacrine cells, horizontal and bipolar cells), glial cells (Müller cells and astrocytes) and vascular cells (endothelial cells and pericytes).12 Evidence of retinal involvement in AD dementia has been shown in histopathological studies of postmortem specimens.13,14 Associations of AD dementia with common eye diseases with overt clinical signs, such as age-related macular degeneration (AMD), diabetic retinopathy (DR) and glaucoma, have also been reported. In addition to digital retinal photography (figure 1), recent advances in non-invasive retinal imaging technologies allow more detailed interrogation of the different retinal layers, and even deeper structures beyond the retina, such as the choroid including the choroidal vasculature. These retinal imaging technologies, which include...
optical coherence tomography (OCT) (figure 2) and OCT angiography (OCT-A) (figure 3), have provided researchers with further access to detailed retinal neuronal structure (eg, nerve fibre layer, ganglion cell layer and inner-plexiform layer) and microvasculature (eg, foveal avascular zone), respectively. Table 1 shows a glossary of retinal imaging technologies and parameters used in studying AD. Details of these technologies are summarised in online supplemental section 1. In comparison to brain imaging technology, retinal imaging has the advantages of being non-invasive, comparatively low cost, increasingly widely available in non-tertiary (eg, primary care and community) settings, and having different variables for quantifying the structures of retina. The development of next-generation computational techniques such as artificial intelligence (AI) and deep learning (DL) algorithms has further enhanced the potential of data-rich retinal imaging as a promising tool and a source of biomarker for AD, particularly for individuals at preclinical AD stage. However, most of the retinal imaging technologies are still specialised equipment and the interpretation of data requires expertise from ophthalmologists or visual scientists.

In this review, we present an update of the current retinal imaging technologies, recent research findings and future research applications in the study of AD.

### COMMON EYE DISEASES AND AD

Vision itself may be an important stimulus for the maintenance of cognitive health or reflect possible relationships between AD with underlying eye diseases. Population-based and clinical studies have consistently shown that visual impairment, and a range of common eye diseases are associated with dementia and impaired cognitive function. For example, in one study, older persons with visual impairment were twice as likely to have cognitive dysfunction than those with good vision.

Online supplemental table 1 summarises research on the relationship between common eye diseases, including AMD, DR, and open-angle glaucoma, with AD dementia. These epidemiological relationships suggest shared risk factors (eg, hypertension, smoking) and possibly pathogenic pathways (eg, neurodegeneration, amyloid-β deposits, chronic microvascular insults) between these ocular diseases and AD dementia. However, the associations have not been consistently observed in the literature, particularly in studies at a population level using large data linkage. For example, a linkage study using English National Health Service data (AD cohort n=251,073, reference cohort n>2.5M), found no associations between AMD (relative risk 0.86 (0.67–1.08), compared with the reference cohort) and glaucoma (rate ratio 1.01 (0.96, 1.06), compared with the reference cohort) with AD dementia.

Lee et al however suggested that the patterns of associations between eye diseases and AD dementia may be different when the ocular conditions are categorised as recent (diagnosed within 0–5 years) or established (>5 years) diagnoses. They found only established AMD (HR 1.50 (1.25, 1.8)) and recent glaucoma (HR 1.46 (1.08, 1.91)) are associated with AD dementia, while both established DR (HR 1.50 (1.03, 2.15)) and recent DR (HR 1.67 (1.01, 2.74)) are associated with AD dementia. A recent meta-analysis (21 studies, 7876499 study subjects) reported that patients with AD dementia are at greater risk for AMD (OR 2.22, I²=50%), and patients with AMD are also at increased risk of AD dementia/cognitive dementia (OR 2.42, I²=58%). Hence, it is likely that AD dementia and common eye diseases are linked via complex, interlinked, multimechanistic pathophysiology and pathways.

### RETINAL IMAGING MEASURES AND AD

Retinal neuronal layer changes at optic disc and macula

AD is classically characterised by loss of neurons and synapses in the cerebral cortex and specific subcortical regions. Previous histological studies have demonstrated that patients with AD also present with underlying eye diseases. However, most of the retinal imaging technologies are still specialised equipment and the interpretation of data requires expertise from ophthalmologists or visual scientists. In this review, we present an update of the current retinal imaging technologies, recent research findings and future research applications in the study of AD.

## Embryological

- During embryonic development, the retina and optic nerve originate from the diencephalon. The retina maintains its connection with the brain via the optic nerve after birth, being an integral component of the CNS.

## Anatomical

- Anatomically, the layered cytological and vascular structures and the presence of a blood barrier are similar in the retina and the brain. The retinal layers are composed of several types of neurons including the retinal ganglion cell (RGC) which comprises a cell body, dendrites and an axon, similar to neurons in the CNS. In addition, the RGC axons, which collectively form the optic nerve, are myelinated by oligodendrocytes and are ensheathed by all three layers of meninges. Furthermore, the retinal tissue is isolated by the blood–retinal barrier which maintains a distinct immunological and physiological environment, similar to the blood–brain barrier. In terms of vascular structure, both the cerebral and the retinal microvasculature components are surrounded by a single layer of endothelial cells, which are non-fenestrated and possess similar intercellular tight junctional complexes. Both are also surrounded by the perivascular end feet from astrocytes. The choroid, the primary vascular supply for the outer retina, is sandwiched between the retina and the sclera. This has one of the highest blood flows per volume unit of any structure in the body.

## Physiological

- There are many physiological similarities between retina and brain. First, a NVU is present in both retina and brain, widely known as the ‘blood–retinal barrier’ and ‘blood–brain barrier’, respectively. The NVU allows functional coupling and interdependency of neurons, glia and the vasculature, for example, regulating blood flow in response to neural activity or metabolic demands. Retinal vascular autoregulation is achieved by retinal glial-synaptic interaction. Second, similar to the CNS neurons, the RGCs produce an identical response to insults, including axonal degeneration, myelin destruction, scar formation and secondary degeneration. In addition, the RGCs have limited regenerative ability after injury. Third, the retina is considered an immune-privileged site and contain similar collection of cell-surface molecules, immunoregulatory molecules and cytokines. Moreover, both cerebral and retinal microglia show phagocytic properties and phagocytose injured neurons. The cerebral vasculature is devoid of autonomic innervation beyond the pia vessels. Similarly, there is no autonomic innervation to the retinal vasculature beyond the level of the lamina cribrosa (except the choroidal circulation). Finally, both the inner retinal and the cerebral circulation are under fine control of the autoregulatory mechanism, which consists of myogenic and metabolic components.
have loss of retinal ganglion cells (RGCs) and their axons. A more recent postmortem study further suggested that the number of melanopsin RGCs, photoreceptors driving circadian phototransmission, may be reduced in AD. These observations have been the basis of clinical studies using OCT to determine the relationship between different retinal layers and AD.

The retinal nerve fibre layer (RNFL) surrounding the optic disc (peripapillary RNFL) reflects RGC axons (figure 1). RNFL thickness can be measured by techniques including time-domain OCT (first generation of OCT) as well as confocal scanning laser ophthalmoscopy (SLO) and scanning laser polarimetry. These studies showed that in patients with AD dementia, there is a significant reduction in RNFL thickness compared with age-matched cognitively normal controls.

Spectral-domain OCT (SD-OCT) and swept-source OCT, a newer generation of OCT, provides information on inner retinal layers with greater resolution, such as the ganglion cell layer and the inner plexiform layer (figure 2). SD-OCT is now routinely used to not only measure peripapillary RNFL but also to assess RGC cell body and dendrites together by segmenting and quantifying the thickness of the ganglion cell inner plexiform layer (GC-IPL, a combination of the ganglion cell layer and the inner plexiform layer) at the macula, since this region contains more than 50% of the total RGCs volume. Numerous studies have investigated the association between SD-OCT measures and AD (online supplemental table 2). These studies first showed that SD-OCT measurements of both peripapillary RNFL (inter-visit intraclass correlation coefficient (ICC) 0.927 (range 0.845–0.961) and coefficients of variation (CoV) 3.83% (range 2.71%–5.25%)), and GC-IPL (inter-visit ICC was 0.968 (0.941–0.985), and CoV was 1.91% (range 1.24%–2.32%) are reproducible in patients with cognitive impairment. Second, while a few studies have reported thicker retinal layers in eyes of patients with AD dementia compared with controls, or no significant thickness differences, the majority of studies, including a meta-analysis, indicate that patients with AD dementia have thinner peripapillary RNFL (standardised mean difference (SMD) = −0.67; I² = 89%) and macular GC-IPL (SMD = −0.46, I² = 71%) compared with controls, consistent with a human postmortem study.

Of the two SD-OCT measurements, some studies suggested that macular GC-IPL may be more sensitive than peripapillary RNFL for assessing neurodegeneration related to AD. For example, Cheung et al reported that macular GC-IPL has a better performance to discriminate AD from normal controls than that of peripapillary RNFL (area under receiver operating characteristic curves (AUROCs) 0.685 vs 0.601), adjusting for age and gender. Figure 2B,C shows an example of GC-IPL and RNFL measurement in a MCI subject with a positive cerebral amyloid PET imaging. Finally, these OCT studies are also consistent with research on other neurodegenerative diseases, such as patients with Parkinson disease and Lewy body dementia, who also have thinner RNFL and thinner inner retinal layers. Furthermore, thinner RNFL, GC-IPL and ganglion cell layer are also associated with reduced cerebral grey matter and white matter volumes and brain volume measured from MRI.

Several possibilities have been proposed to explain the above findings on thinning of the retinal neuronal layer. First, the cerebral pathology of AD may affect the neuronal connections of the visual tract and cause retrograde degeneration of the optic nerve and retinal layers, resulting in thinner retinal neuronal and axonal layers including RNFL and GC-IPL. However, peripapillary RNFL could not discriminate controls from AD patients with posterior cortical atrophy, a clinical variant of AD with dominant involvement of parieto-occipital (ie, visual) cortex, where one would explicitly expect this retrograde degeneration to occur. Alternatively, it is speculated that cerebral signs of AD pathology including amyloid-β plaques, fibrillar tau and signs of neuroinflammation occur simultaneously both in the brain and the retina, underlining a common pathogenesis linking retinal neuronal and axonal layer changes and AD. The less common observation of thickened RNFL in AD may be explained by occurrence of reactive gliosis in inner retina, an inflammatory response, during early stages of AD, which may precede retinal neuronal layer thinning or mask underlying subtle retinal neuronal layer thinning on OCT. There are fewer prospective studies on the longitudinal relationship of SD-OCT measures and development of cognitive function deterioration and AD dementia.
Figure 2  (A) Cross-sectional view of retina captured by optical coherence tomography (OCT). (B) Assessment of macular ganglion cell-inner plexiform layer (GC-IPL) and (C) peripapillary retinal nerve fibre layer (RNFL) of a subject who presented with mild cognitive impairment having a positive cerebral amyloid positron emission tomography (PET) imaging, measured with Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, California, USA) (OD=right eye; OS=left eye). No retinal disorders were observed in this subject. The GC-IPL thickness map (B) and peripapillary RNFL thickness map (C) use a false colour coding with warm colours represent high and cool colours represent low thickness values. The software further compares the measured thickness to the device’s internal normative age-matched database and generates a deviation map. Thinner GC-IPL and RNFL thicknesses are observed in this example in prodromal stage. (D) A cross-sectional view of choroidal vasculature in an example of a cognitively normal subject; and (E) in a subject with Alzheimer’s disease (AD) dementia (Global Clinical Dementia Rating Score of 1). The choroid is indicated by red arrows. Choroidal-scleral interface can be clearly identified. The subject with AD dementia had a thinner choroidal layer compared with the cognitively normal subject.
Rotterdam Study \((n=3289)\) showed that a thinner peripapillary RNFL is associated with a higher risk of developing dementia \((\text{per } 1 \mu\text{m decrease } \text{HR} 1.02 \ (1.01, 1.04))\), including AD dementia \((\text{per } 1 \mu\text{m decrease } \text{HR} 1.02 \ (1.01, 1.04))\), independent of cardiovascular risk factors.\(^{27}\) In addition, longitudinal data from the UK Biobank \((n=32\,038)\) enrolling healthy community dwelling participants also showed that thinner RNFL is a precursor of future decline in cognitive function.\(^{28}\) Specifically, they found that those in the lowest two quintiles of baseline peripapillary RNFL distribution had twice the likelihood of developing a decline in cognitive function over a 3-year follow-up interval compared with those in the top RNFL quintile.\(^{28}\) In regard to GC-IPL, data from the Rotterdam Study showed that thinner GC-IPL is only associated with prevalent dementia \((\text{per } 1 \mu\text{m decrease } \text{OR} \ 1.03 \ (1.00, 1.09))\), but not with incident dementia \((\text{per } 1 \mu\text{m decrease } \text{HR} \ 1.02 \ (0.99, 1.05))\) or incident AD dementia \((\text{per } 1 \mu\text{m decrease } \text{HR} \ 1.02 \ (0.99, 1.05))\).\(^{27}\) The Rotterdam Study group speculated that there may be a time delay between optic nerve degeneration \(\text{reflected by RNFL thinning}\) and RGC loss \(\text{reflected by GC-IPL thinning}\) as the damage to the optic nerve may cause swelling or gliosis formation of the RGC axons \(\text{ie, RNFL}\). Therefore, the neurodegenerative process may manifest itself in the retina

---

### Table 1 Glossary of retinal imaging technologies and parameters used in studying Alzheimer's disease

<table>
<thead>
<tr>
<th>Retinal imaging technologies</th>
<th>Parameters measured from retinal imaging</th>
<th>Descriptions of the parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spectral-domain optical coherence tomography (SD-OCT)</td>
<td>Peripapillary retinal nerve fibre layer (RNFL) thickness</td>
<td>A thickness of RNFL layer in peripapillary region to assess retinal ganglion cell (RGC) axon. Traditionally, peripapillary RNFL thickness is calculated along a 3.4mm circle around optic disc.</td>
</tr>
<tr>
<td>Macular ganglion cell inner plexiform layer (GC-IPL) thickness</td>
<td>A combined thickness of ganglion cell layer and inner plexiform layer in macular region to assess RGC cell bodies and dendrites.</td>
<td></td>
</tr>
<tr>
<td>Peripapillary retinal nerve fibre layer (RNFL)</td>
<td>A thickness of RNFL layer in peripapillary region to assess retinal ganglion cell (RGC) axon.</td>
<td></td>
</tr>
<tr>
<td>Macular ganglion cell complex (GCC) layer</td>
<td>A combined thickness of RNFL, ganglion cell layer and inner plexiform layer in macular region to assess RGC axon, cell bodies and dendrites.</td>
<td></td>
</tr>
<tr>
<td>Macular thickness or volume</td>
<td>A thickness or volume between inner limiting membrane and the retinal pigment epithelium at macular region.</td>
<td></td>
</tr>
<tr>
<td>Retinal imaging with retinal fundus photography</td>
<td>Central retinal arteriole equivalent (CRAE)</td>
<td>A summary index reflecting the average width of retinal arterioles.</td>
</tr>
<tr>
<td>Optical coherence tomography (OCT-A)</td>
<td>Vessel density</td>
<td>A measure of the area occupied by blood vessels (\text{including capillaries}) over total area within the interested region.</td>
</tr>
<tr>
<td>Foveal avascular zone (FAZ) area</td>
<td>A capillary-free area in the central macula with highest cone photoreceptor density and oxygen consumption.</td>
<td></td>
</tr>
<tr>
<td>Optical coherence tomography with enhanced depth imaging (OCT-EDI)</td>
<td>Choroidal thickness or volume</td>
<td>A thickness or volume between the outer border of retina pigment epithelium and sclera-choroidal interface.</td>
</tr>
<tr>
<td>Dynamic vessel analysis</td>
<td>Flicker-induced vessel dilation</td>
<td>An average percentage increase in the vessel diameter in response to the flickering-light during measurement cycles, relative to the baseline diameter size.</td>
</tr>
<tr>
<td>Retinal oximetry</td>
<td>Retinal vessel oxygen saturation</td>
<td>A measure of the oxygen saturation in retinal arterioles and venules to detect changes in oxygen metabolism.</td>
</tr>
<tr>
<td>Ultra-widefield retinal photography</td>
<td>Presence of peripheral hard drusen</td>
<td>Presence of small and distinct yellow deposits under retina in the periphery.</td>
</tr>
<tr>
<td>Fluorescence lifetime imaging ophthalmoscopy (FLIO)</td>
<td>Fluorescence lifetime</td>
<td>A measure to describe the average time a single fluorophore remains in its electronically excited state after absorbing the energy of a photon and before returning to the ground state by emitting a photon.</td>
</tr>
</tbody>
</table>
initially as thinner peripapillary RNFL, after which thinning of GC-IPL follows.\textsuperscript{27}

**Retinal arteriolar and venular changes**

There is also substantial evidence indicating a vascular disease component in AD pathophysiology. Clinical and epidemiological studies show that vascular diseases and their risk factors commonly accompany AD.\textsuperscript{32} Vascular risk factors are associated with higher cerebral Aβ burden.\textsuperscript{33} Comorbidity of cerebrovascular disease and amyloid-β is associated with cognitive decline and neurodegeneration.\textsuperscript{34} In particular, microvascular or small vessel disease is now thought to be a major contributor to dementia and cognitive decline.\textsuperscript{34–35} For example, an autopsy-based neuropathological study showed that a large majority of patients diagnosed with AD without clinical evidence of mixed (vascular) dementia had microvascular pathology including lacunes, cerebral microbleeds and multiple microinfarcts indicative of small vessel disease.\textsuperscript{35}

The retinal circulation of arterioles and venules, measuring 100–300μm in size, are the only optically accessible small blood vessels in the human body. The retinal vasculature can be imaged by either conventional retinal photography (figure 1A) or dye-based fluorescein angiography. However, because dye-based fluorescein angiography is invasive, conventional retinal photography has been the most commonly used retinal imaging technique to capture clinical vascular disease signs, such as those typically seen in patients with diabetes or hypertension (eg, retinal haemorrhage, cotton wool spots, microaneurysms, arteriovenous nicking, enhanced arteriolar light reflex). In addition to these qualitative signs, computerised algorithms have been developed to measure quantitative changes in the retinal vasculature, for instance, the calibre of arterioles and venules.\textsuperscript{36–39} Furthermore, geometric patterns of the retinal vasculature may also provide information on microvascular health. Based on Murray’s principle of minimum work, the human circulatory system is a branching system that conforms to optimum design principal to minimise the energy required to maintain blood flow.\textsuperscript{40} Algorithms estimating a number of retinal geometric parameters such as fractal dimension, tortuosity and bifurcation have been further reported.\textsuperscript{41–43} These algorithms capture deviations from the normal optimal architecture of the retinal vascular network. Several algorithms can be used to analyse retinal photographs taken by conventional retinal cameras. Figure 1B,C shows examples of quantitative retinal vasculature analysis using a widely used software, the Singapore I Vessel Assessment (SIVA), in a cognitively normal subject and a subject with AD, respectively. Other software and algorithms include IVAN (Integrative Vessel Analysis),\textsuperscript{44} VAMPIRE (Vascular Assessment and Measurement Platform for Images of the RETina)\textsuperscript{45} and QUARTZ (QUAntitative Analysis of Retinal vessel Topology and sZe).\textsuperscript{46}

Online supplemental table 2 summarises the clinical studies reporting relationship of quantitative retinal vasculature analysis from retinal photographs with AD. In general, these studies showed a sparser retinal vascular network (indicated by decreased retinal vascular fractal dimension) is associated with AD dementia.\textsuperscript{40–44} Poorer cognitive test score performances\textsuperscript{33,34} and MRI markers of cerebral small vessel disease.\textsuperscript{35} For example, Frost et al found that decreased arteriolar fractal dimension (1.201 vs 1.235, p=0.008) and venular fractal dimension (1.171 vs 1.210, p<0.001) in AD dimension, compared with controls.\textsuperscript{39} Cheung et al found that decreased arteriolar fractal dimension (per-SD decrease OR 1.35 (1.08, 1.68)) and venular fractal dimension (per-SD decrease OR 1.47 (1.17, 1.84)) are associated with AD dementia.\textsuperscript{30} These findings suggest that changes in the retinal vascular fractal dimension may also reflect a departure from optimal integrity of the cerebral microcirculation (eg, rarefaction) related to cognitive impairment.\textsuperscript{45} Studies also showed that narrower retinal venular calibre is associated with AD dementia, which may be related to an increased venous wall thickness due to collagen deposition in cerebral veins.\textsuperscript{30,40} Although some studies observed significant associations between retinal vascular tortuosity and AD dementia, the relationship remains equivocal. Cheung et al\textsuperscript{40} found that both increased retinal arteriolar (per-SD increase OR 1.80 (1.40, 2.31)) and venular tortuosity (per-SD increase OR 1.94 (1.48, 2.53)) are associated with AD dementia, while Williams et al\textsuperscript{41} found that decreased retinal arteriolar (per-SD increase OR 0.78 (0.63, 0.97)) tortuosity is associated with AD dementia. It is noted that increased retinal vascular tortuosity is associated with higher blood pressure and diabetes,\textsuperscript{33,42} and difference between studies may reflect differences in prevalence of hypertension and diabetes (eg, participants in the study by Cheung et al had higher prevalence of both hypertension and diabetes than participants in studies by Williams and Frost). On the other hand, if different pathophysiological mechanisms occur at different stages of AD,\textsuperscript{47} associations with retinal parameters would be expected to change correspondingly. Thus, clinical and demographic data and stages of AD should be taken into account when interpreting findings across studies.

**Retinal capillary changes**

In addition to the arterioles and venules, changes at the capillary level (5–15 μm) may also be studied for their relationship to AD.\textsuperscript{48,49} The retinal capillary network can now be imaged by dye-free OCT-angiography (OCT-A) which visualises capillary levels at different levels and sites of the retina: the superficial capillary plexus, the deep capillary plexus and the radial peripapillary capillary plexus. Images captured by OCT-A (figure 3) have helped to identify and quantify capillary level abnormalities in primary retinal diseases such as DR and AMD.\textsuperscript{50–52} Online supplemental figure 1 shows image processing steps adopted to quantify the capillary networks from OCT-A images.\textsuperscript{53} Recent reports (online supplemental table 2) have identified changes in the retinal capillary networks using OCT-A in AD dementia and preclinical AD.\textsuperscript{54–56} For example, Bulut et al observed decreased capillary network density (45.5% vs 48.7%, p=0.002) and an enlarged foveal avascular zone area (0.47 mm\textsuperscript{2} vs 0.33 mm\textsuperscript{2}, p=0.001) in 26 patients with AD dementia, compared with 26 age-matched and sex-matched controls.\textsuperscript{57} O’Byrhim et al further demonstrated that enlarged foveal avascular zone measured from OCT-A is associated with preclinical AD (0.364 mm\textsuperscript{2} vs 0.275 mm\textsuperscript{2}, p=0.002), as defined by the presence of amyloid-β biomarkers from PET or CSF, compared with those amyloid-β-negative control subjects (n=32 participants).\textsuperscript{58} In addition, they reported that foveal avascular zone area can discriminate participants with biomarker positive and biomarker negative with an AUROC of 0.801.\textsuperscript{34} These observations are in line with disturbances in the morphology and function of cerebral capillary networks observed as antecedents to neurodegenerative changes associated with AD in animal models and postmortem studies.\textsuperscript{56–58} However, the current literature is not entirely consistent. For example, Querques et al and den Haan et al did not observe any differences in capillary network density and foveal avascular zone between patients with AD dementia and controls.\textsuperscript{51,52} Van de Kreeke et al have reported that an increased capillary network density in patients with preclinical...
AD, instead of a decreased one, compared with controls (inner ring macula difference: 0.81%, p=0.002; outer ring macula difference: 0.50%, p=0.024; and around optic nerve head difference: 0.83%, p=0.015), which may be due to an inflammatory state of the retina in the early stages of amyloid-β accumulation.57 It is noteworthy that similar to the literature on retinal imaging technologies as mentioned above, the diagnosis of AD dementia differs between different OCT-A studies, and most of studies are currently limited by small sample size and the inability to adequately account for potential confounding factors (eg, diabetes, axial length of the eyeball).

**Choroidal vasculature changes**

Deep to the retina, the choroid contributes blood supply to the outer retina. In addition to the retinal vasculature (arterioles, venules, capillary network), SD-OCT with enhanced depth imaging, or swept-source OCT, has now made it possible to image the choroidal vasculature. Figure 2DE shows a cross-sectional view of the choroidal vasculature imaged by SS-OCT in a cognitively normal subject and a subject with AD, respectively. A few case–control studies have observed thinning of the choroidal layer as assessed by SD-OCT with enhanced depth imaging in AD dementia (online supplemental table 2).567,579,580 For example, Gharbiya et al first reported reduced subfoveal choroidal thicknesses (200.9 μm vs 266.1 μm, p=0.001) in 21 patients with mild to moderate AD dementia compared with controls. It was postulated that choroidal thinning indicates an abnormal choroidal blood supply associated with vasoregression or atrophic changes related to a series of pathologic events (eg, inflammatory cascade) triggered by amyloid-β deposition in the brain.580,581 In a recent prospective study (n=78), a larger reduction in choroidal thicknesses is observed in AD dementia over a 12-month follow-up (changes in subfoveal choroidal thickness: −10.47 μm vs −2.0 μm), compared with controls.581 This finding is consistent with a report on postmortem eyes from patients with AD dementia and animal models of AD.582 Furthermore, a population-based study with more than 3000 participants found reduced subfoveal choroidal thickness is significantly associated with lower Mini Mental Status Examination score, in line with the findings in AD dementia eyes.583

**Vasodilatory response changes**

The retinal NVU contains neurons, glial cells and vascular cells, similar to the NVU in the CNS.13 Flickering light stimulates activity of the neural retina and leads to retinal vessel dilation as a result of the release of vasodilating factors, especially nitric oxide, from endothelial and neural cells. This dynamic reaction of retinal vessels to flickering light is influenced by neurovascular coupling and can therefore be used to assess the function of NVU in the retina.584 The flicker-induced vasodilatory response can now be measured non-invasively using a dynamic vessel analyser (DVA). A few studies have explored to use DVA to investigate the flicker-induced vasodilatory response in AD, but the current findings are still preliminary and inconclusive. Kotliar et al observed that overall flicker-induced vasodilatory response is delayed in AD dementia (arterial time to reach 30% of maximum dilation: 7.0 s vs 5.0 s, p<0.001) compared with controls, suggesting delayed arterial reaction in AD.584 They also demonstrated that this DVA parameter can discriminate AD dementia with an AUROC of 0.853.50 However, Golzan et al only found a positive correlation between neocortical amyloid-β standardised uptake value ratio measured by PET with the amplitude of retinal arterial pulsations, but did not observe any correlations with dynamic flicker-induced retinal arteriolar or venular dilation in an elderly cohort.51 It is noteworthy that patients with diabetes and DR have reduced flicker-induced vasodilatory responses.585,586 Kotliar’s and Golzan’s studies did not specifically exclude those with diabetes and with ocular diseases, which may confound the results reported. Queques et al recently conducted a similar study but excluded subjects with diabetes and optic nerve or retinal diseases and reported that retinal arteriolar dilation in response to flickering light is reduced in the AD dementia group, compared with controls (0.77% vs 3.53%, p=0.002) and the MCI group (0.77% vs 2.84%, p=0.045).571 This study suggests that the neurovascular coupling of retinal vessels in AD dementia is impaired, especially in retinal arterioles, and the effect is independent of diabetes. This observation suggests that decreased retinal and cerebral blood flow (ie, hypoperfusion) might impair the endothelial function and the production of nitric oxide, which is vital for the vasodilatation process.52,571

**Retinal vessel oxygen saturation changes**

The retina is one of the most metabolically active tissues in the human body. Retinal vessel oxygen saturation can now also be measured non-invasively, based on estimation of haemoglobin oxygen saturation in retinal vessels by taking two simultaneous retinal photographs with 570 and 600 nm light.587 Studies have reported that retinal oxygen saturation in arterioles and venules is significantly higher in both AD dementia and MCI eyes compared with controls.588,589 Einarsdottir et al showed that retinal arterioles have 94.2%±5.4% oxygen saturation in moderate AD compared with 90.5%±3.1% in healthy subjects (p=0.028). Retinal venules were 51.9%±6.0% saturated in moderate AD compared with 49.7%±7.0% in healthy subjects (p=0.02).588 Olafsdottir et al further showed that arteriolar and venular oxygen saturation was increased in patients with MCI compared with healthy individuals (93.1%±3.7% vs 91.1±3.4%, p=0.01; 59.6±6.1% vs 54.9±6.4%, p=0.001, respectively).589 These studies demonstrate a decreased metabolic activity in the retina and this exploratory finding may provide new insight into the pathophysiology of AD related to hypometabolism.

**Peripheral retinal changes**

Drusen deposits are the hallmark of AMD. Amyloid-β has been found in druse deposits in the retina.590 In a recent pilot study, Csinkcik et al used ultra-widefield scanning laser ophthalmoscopy and examined AMD-like drusen deposits in a wider field of the peripheral retina, in addition to the macular region.42 They found that patients with AD dementia are more likely to have drusen deposits in the peripheral retina compared with controls (25.4% vs 4.2%, p=0.04), especially in the superior nasal quadrant.42 Online supplemental figure 2 shows an example of presence of drusen deposits in the peripheral retina imaged by ultra-widefield scanning laser ophthalmoscopy in a subject with AD dementia. In addition, Ukalovin et al also found that the severity of cerebral amyloid angiopathy, a vascular feature associated with AD dementia and cognitive decline,591 is correlated with the number of drusen in the peripheral retina from post-mortem AD eyes (r=0.78, p<0.05).590 The preliminary findings from these exploratory studies suggest that retinal abnormalities related to AD are also present in peripheral retina, in addition to retinal changes measured from conventional retinal imaging areas focused centrally (ie, macular and optic disc regions). Further studies are required to determine whether the peripheral retinal changes have similar or additional predictive value for
AD dementia or cognitive decline, and to develop better understanding of the significance of these associations, particularly since peripheral changes can also occur in the intermediate to advanced stage of AMD.593

**Retinal fluorescence lifetime changes**

The retina has several kinds of endogenous fluorophores, including lipofuscin, advanced glycation end products, collagen, melanin and elastin. Retinal fluorophores can be excited by monochromatic light (eg, laser) and gain a higher level of energy before returning to their ground state by emitting photons of longer wavelengths than the exciting light (ie, fluorescence lifetime).594 Each fluorophore possesses a characteristic fluorescence lifetime. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a technique for measuring fluorescence lifetime, which is calculated by the average amount of time a fluorophore remains in the excited state following excitation, to allow detecting metabolic alterations in the retina for various retinal disease such as AMD at an early stage.594 Jentsch et al found that a longer retinal fluorescence lifetime measured by FLIO is correlated with higher tau protein concentration in CSF in patients with AD dementia.595 In a pilot study, Sadda et al also found that subjects with preclinical AD, compared with controls, have longer retinal fluorescence lifetime (593.9±93.3, 454.4±38.6 µs; 475.0±71.6, 394.1±28.2 µs in short spectral channel and long spectral channel of AD and control groups, respectively, p=0.036 and 0.024), which is also correlated with GC-IPL thickness, amyloid-β and tau protein in CSF.596 The preliminary findings from these exploratory studies suggest that the fluorophore composition in the retina may be related to AD.

**Age-related effect on the retina**

Age-related changes are well reported in the retinal neuronal and vascular structures as well as in the choroid. RNFL and GC-IPL thicknesses decrease with increasing age in healthy adults.597-599 In a longitudinal analysis, the mean rate of change of average RNFL is −0.52 µm/year in normal individuals.5100 Similarly, narrower retinal vessel calibre, straighter retinal vessels, sparser retinal vasculature and decreased choroidal thickness are correlated with increasing age in healthy adults as reported from population-based studies.5101-5102 In the Singapore Malay Eye Study-2, for each 1-year increase in age, subfoveal choroidal thickness decreased by 3.10 µm.5104 These age-related effects on retinal imaging measures are considered as a physiological process; however, the current measurements are not standardised by age. Although most of the reported studies were case–control study design matched with age or included age as a confounding factor in the statistical models, how to taking age into account during image interpretation in clinical practice should be further addressed.

**Evidence of AD pathology in the retina is equivocal**

Amyloid-β protein plaques and neurofibrillary tangles comprised of hyperphosphorylated tau protein are pathological hallmarks of AD. Several histopathological studies have identified retinal amyloid-β deposits in animal models of AD582,5106 as well as human subjects with definite AD511 and suspected early AD.544 The majority of amyloid-β deposits are in the GC-IPL546 and some show perivascular clustering.511 A clinical study by Koronyo et al demonstrated an increased presence of amyloid-β in the retina of patients with AD dementia compared with controls, especially in the peripheral superior quadrant, often clustered along blood vessels.513 These retinal amyloid-β plaques qualitatively resemble those found in the cerebrum of subjects with AD dementia and were only detected in minimal quantities in age-matched non-AD controls.14,51 Moreover, it is possible that accumulation of retinal amyloid-β plaques occurs earlier than in the brain and the amount increases with disease progression.544 Similar to those in the brain, retinal amyloid-β deposition also showed to be associated with marked neurodegeneration. La Morgia et al demonstrated that there is amyloid-β deposition in and around degenerating melanopin RGCs, suggesting amyloid-β is toxic to retinal neurons.54 Koronyo et al also reported that, when compared with matched controls, reduced cell counts in the RGC layer, inner nuclear layer and outer nuclear layer are observed in patients with AD dementia along with accumulation of amyloid-β.51 In line with these findings, the neurotoxicity of amyloid-β to retinal neurons has also been shown in both cell-line studies5107,5108 and animal model studies.543,5109,5110 These findings from animal studies are therefore consistent with the observations of clinical studies reporting thinner RNFL and GC-IPL in patients with AD dementia discussed above. Apart from retinal amyloid-β deposition, animal studies also showed that there are tau aggregates in the retina of transgenic mice with a tau mutation.5111 These mice display abnormal neurotrophic factor signalling, increased susceptibility to excitotoxic damage, early axonopathy and functional deficits of RGCs.5111,5112

However, it is noteworthy that the evidence of AD pathology in the retina is not consistent across the literature, and presence of amyloid-β or tau in the retina still remains controversial.5113 For example, Schön et al reported that the postmortem retinas of patients with AD dementia only contain hyperphosphorylated tau but not amyloid-β or fibrillar tau aggregates.514 Several studies did not find any AD-related pathology in AD retinas and could not replicate previous findings.52,514,5113 Haan et al found that despite amyloid-β/amyloid precursor protein being present in postmortem AD retinas, there are no amyloid-β/amyloid precursor protein-related differences, but rather tau-related changes, between AD and control retinas.5115 It is noted that adoption of different tissue processing methods and immunostaining protocols, and comorbidity of ocular diseases and AD may possibly explain some discrepancies. On the other hand, although amyloid is proclaimed as a toxic substance, it triggers the pathological process in the very initial state of the disease. For instance, hippocampal volume is characteristically reduced in AD with congruent tau pathology in the corresponding region, whereas it lacks amyloid pathology in hippocampal region.5117 Findings on the presence of amyloid-β or tau in the retina should be further replicated before we assume that AD pathology in the retina is present. Furthermore, studies on relationships among amyloid, tau and retinal changes in the pathological study of AD are warranted.

**FUTURE RESEARCH**

Studies to date suggest a range of retinal imaging technologies can be used to study different stages of AD. However, more research is clearly needed. For example, studies on relationships between retinal imaging measures and ‘standard’ biomarkers of AD pathophysiology, as well as direct comparisons between different retinal imaging measures to determine relative sensitivity/specificity of each measure for AD clinical diagnosis or biomarker status are warranted. Furthermore, some neuronal and vascular changes in the retina are similar between AD and ocular disease. Some of these researches are discussed below.
Framework of development and validation of retinal imaging as a source of biomarkers

Disease-modifying treatments for AD are most likely to be successful if initiated early in the disease process, ideally before irreversible neurodegeneration and functional decline set in.\(^\text{13,34}\) Biomarkers may aid in risk profiling to identify those at greatest risk, detection of pathology at the earliest possible stage, and by providing endpoints for trials that identify benefit earlier in the natural history of the disease, thus accelerating the development of new treatments. Therefore, discovering effective biomarkers of AD is a priority for development of new treatment.

A biomarker is defined as an objective substance, characteristic or other parameter of a biological process that enables the assessment of a disease risk or prognosis and provides guidance for diagnosis or monitoring of treatment.\(^\text{10}\) Different groups have proposed frameworks or roadmaps for biomarker development and validation for AD.\(^\text{3,10,35,36}\) For example, Frisoni \textit{et al} proposed a five-phase framework to foster the clinical validation of biomarkers for an early diagnosis of AD, adapted from the approach for cancer biomarkers. These include preclinical exploratory studies, clinical assay development for AD pathology, retrospective studies using longitudinal data available in repositories, prospective diagnostic accuracy studies and disease burden reduction studies.\(^\text{36}\) A consistent framework to assess the validity of biomarkers for different clinical purposes is essentially important for implementation and clinical use in AD.

Currently, retinal imaging technologies cannot yet be considered a source of biomarker of AD as many areas of research remain conflicting and evidence-based guidelines on the use and interpretation of retinal imaging are currently lacking. Most published studies have focused on demonstrating measure difference compared with controls and associations (linear or logistic regression models) between a set of retinal imaging measures with AD dementia only. Moreover, studies on preclinical AD are largely lacking. Table 2 summarises the findings on retinal neuronal changes, retinal capillary changes, retinal arteriolar and venular changes, and choroidal vasculature changes. In addition, some of the reported associations may not account for potential confounding factors (eg, ocular diseases and systemic conditions) and clinical stages of AD. The current retinal imaging features (eg, RNFL loss) are also non-specific to AD and not designed to fully describe and characterise the spectrum of AD-related disorders. For example, there is a lack of consensus on how best to differentiate between retinal changes seen in glaucoma and AD dementia. Typically, in patients with glaucoma, the reduction in peripapillary RNFL occurs in inferior and superior sectors\(^\text{51,58}\) but the studies in AD dementia have also shown similar patterns of RNFL reduction.\(^\text{18}\) Many prior studies have also not evaluated retinal imaging for a specific clinical purpose such as screening, diagnosis, prognosis or monitoring of AD dementia. Appropriate statistical analysis of biomarker validation should be performed (eg, performing area under the receiver operating characteristic curve to evaluate discriminative performance). Finally, the definition of AD in the reports did not consistently include confirmation from current available biomarkers. Thus, there is inadequate evidence on the clinical usefulness of retinal imaging measures as a biomarker for AD.

We suggest the following framework of research (online supplemental table 3). First, studies should be designed and conducted to validate biomarkers from retinal images with a specific clinical purpose (eg, screening or risk stratification). Second, diagnosis of AD should be defined in a consistent manner with the latest available criteria (eg, confirmation with current biomarkers). Third, standard statistical measures of accuracy of biomarkers should be reported. For example, if a study evaluates measures from retinal images as a potential screening tool, the measures should be compared with controls and other clinical biomarkers. For instance, the association is equivocal. Both increased and decreased retinal vascular tortuosity were observed.

### Table 2 The summary of current findings on retinal neuronal changes, retinal capillary changes, retinal arteriolar and venular changes, and choroidal vasculature changes

<table>
<thead>
<tr>
<th>Biomarker Type</th>
<th>Preclinical AD or MCI</th>
<th>AD dementia</th>
</tr>
</thead>
</table>
| Retinal neuronal changes                             |  ► Some studies showed reduced peripapillary RNFL, macular GC-IPL and GCC thicknesses, compared with controls  
 ► But a few studies showed no differences in the measures, compared with controls and AD dementia  
 ► A few studies also showed thickened peripapillary RNFL and macular GC-IPL thicknesses in MCI, compared with controls |  ► Majority of studies and meta-analysis showed reduced peripapillary RNFL, macular GC-IPL and macular thicknesses, compared with controls  
 ► But a few studies showed no differences in the measures, compare with controls  
 ► A few studies also showed thickened peripapillary RNFL and macular GC-IPL thicknesses, compared with controls  
 ► In a population-based study, reduced peripapillary RNFL associated with incident AD dementia |
| Retinal capillary changes                            |  ► Majority of studies showed decreased vessel density and enlarged foveal avascular zone area, compared with controls  
 ► But a few studies showed no differences in the measures, and one study showed increased vessel density in preclinical AD, compared with controls |  ► Majority of studies showed decreased vessel density and enlarged foveal avascular zone area, compared with controls  
 ► But a few studies showed no differences in the measures. |
| Retinal arteriolar and venular changes                |  ► No data  
 ► Majority of studies showed narrower CRVE, compared with controls  
 ► Majority of studies showed decreased arteriolar and venular fractal dimensions, compared with controls |  ► No data  
 ► The association is equivocal. Both increased and decreased retinal vascular tortuosity were observed |
| Choroidal vasculature changes                        |  ► No data  
 ► Reduced choroidal thicknesses, compared with controls  
 ► A larger reduction in choroidal thicknesses over a 12-month follow-up, compared with controls |  

AD, Alzheimer’s disease; CRVE, central retinal vein equivalent; CRVE, central retinal artery equivalent; GCC, ganglion cell complex; GC-IPL, ganglion cell-inner plexiform layer; MCI, mild cognitive impairment; RNFL, retinal nerve fibre layer.

tool, the sensitivity, specificity, false-positive and false-negative rates of retinal imaging should be reported. The degree of abnormality and the prevalence (ie, how frequent is the abnormality found in AD) should be described. Fourth, studies should be designed carefully to take into account many age-related ocular conditions. The effects of ocular factors (eg, axial length of the eyeball) on retinal imaging measures and the associations with common eye diseases (eg, glaucoma and AMD) should be determined and considered in the analysis and interpretation. Fifth, the reproducibility of the retinal imaging measures should be determined, particularly if retinal imaging is used for disease diagnosis and monitoring on multiple follow-up visits. Finally, the incremental benefit and cost-effectiveness of retinal imaging, as well as acceptability to patients in different settings, should be evaluated. These areas should be reported in the framework of retinal imaging studies for AD.

**Other new retinal imaging technologies related to AD**

Several new retinal imaging technologies are also being explored which might provide additional value in this field.

Retinal hyperspectral imaging obtains a series of hyperspectral reflectance images, combing both spectral and spatial information, by scanning the retina with a continuous range of wavelength of light. More et al showed that amyloid-β exerts a characteristic influence on the reflectance of light as assessed by retinal hyperspectral imaging and that the magnitude of this effect varies in proportion with the amount of amyloid-β in the retina of AD mouse. This finding was further validated in recent in vivo human clinical studies by showing optical density spectral profiles are different between AD and controls, and who are amyloid-β positive and negative on PET can be discriminated from the reflectance of hyperspectral retinal images with a machine learning–based model for the classification. Hyperspectral imaging technology is also being investigated to identify brain cancer as well as to estimate cerebral metabolism and haemodynamics from brain tissues.

Adaptive optics, improving the performance of optical systems by reducing the effects of optical aberrations, can be employed in scanning laser ophthalmoscopy to achieve very high resolution (~2 μm) in the human retina resulting in the direct visualisation of nerve fibre bundles and other minute retinal features. The authors speculated that the hyperspectral granular membranes are due to inner retinal gliosis which supports a previously established association between AD and glial cell activation in the brain and retina.

Given that the retina is an easily accessible window and connected to the CNS, it is believed that further advance in retinal imaging as well as multimodal, composite biomarkers for AD will be continuously developed.

**Artificial intelligence**

Another major area of future research in the analysis of retinal images is AI. The current retinal imaging measures (eg, reduction in RNFL thickness) are not necessarily specific to AD and not designed to fully describe and characterise the spectrum of AD-related disorders. Recent developments of AI, particularly in DL, have potential to transform imaging technology in healthcare.

DL is based on deep neural networks, involving many layers of linear (convolutional) and non-linear operations trained on previously unfeasible amounts of data.

In retinal imaging, AI and DL technology have been developed in several areas, the two most prominent ones being first, in the assessment of retinal photographs for detection and screening of DR, AMD, glaucoma, and retinopathy of prematurity, and second, the segmentation and assessment of OCT images for diagnosis and screening of major retinal diseases. These studies demonstrate the promise of DL for discovering discriminative latent information associated with AD as well as neurodegenerative disease and cerebrovascular disease from retinal images. For example, using DL, target-specific features are automatically learnt by DL algorithm in the feature extraction stage and numerous unconventional features that are neither noticed by human previously nor examined by appropriate clinical study will also be assessed. DL could be used to recognise specific pattern of retinal changes secondary to AD pathology (ie, ‘retinal fingerprint’ of AD) potentially.

How might AI-based retinal imaging be used potentially? Online supplemental figure 3 shows a proposed pathway of screening AD using retinal imaging. By providing a simple two-tier risk stratification output, this algorithm could assist physicians to identify asymptomatic individuals who are more likely to have AD in the community. The availability of retinal imaging in eye clinics for assessing ocular diseases allows opportunistic screening for AD on a large scale. Introducing retinal imaging in neurology clinics for subjects with memory issues would add a complementary risk profiling tool for assessing the risk of AD. Higher-risk patients could then benefit from subsequent more intensive and specific (but expensive) examinations (eg, PET imaging of CSP analysis for identification of underlying disease pathologies). This would potentially benefit the treatment workflow of AD if a disease-modifying therapy is successfully developed.

**Clinical trials and outcome monitoring**

While retinal imaging cannot fully replace current tests such as PET imaging or CSF analysis for detecting AD pathology (eg, amyloid-β and tau accumulation), retinal imaging offers several unique advantages over current biomarkers. First, retinal imaging offers lower cost methods to identify appropriate study cohorts (ie, cognitively normal individuals with AD-related retinal characteristics) for recruitment into clinical trials of new treatments for dementia (eg, anti-amyloid therapy to delay cognitive decline). Measurements from retinal imaging (eg, neuronal and vascular changes) may also be used to assess optimal or suboptimal therapeutic response to medical intervention. For example, the ENVIS-ion study, which aims to determine the effectiveness of low-dose aspirin in reducing the development of white matter lesion and silent brain infarction, is also validating retinal vascular changes as potential treatment outcomes. In addition, blood-based biomarkers, a less invasive and potentially cheaper approach, are being explored for aiding AD detection at early stage. Combining both retinal imaging and blood-based biomarkers (ie, ‘multiple marker approach’) may increase the accuracy to identify appropriate study cohorts for recruitment into the clinical trials, compared with using only a single marker.

**CONCLUSIONS**

There is an increasing body of research using current and emerging retinal imaging technology to study AD. Newer retinal imaging technologies are increasingly available, are non-invasive, copyright.
and comparatively low cost and easy to use for clinical and population studies. While current research shows promising evidence that many retinal imaging measures show associations with AD, longitudinal studies are lacking and larger replication studies are necessary. A framework for retinal imaging development and validation in AD should be developed and followed by future studies to allow consistent comparison of findings. Newer computational technology, such as AI hold promise to use retinal imaging as a ‘point of care’ level test for screening, early risk assessment and stratification.

Author affiliations
1 Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China
2 Gerald Choa Neuroscience Centre, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Lui Che Woo Institute of Innovative Medicine, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
3 National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK
4 VAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, UK
5 Pharmacology, National University Singapore Yong Loo Lin School of Medicine, Singapore
6 Memory Aging and Cognition Centre, National University Health System, Singapore
7 Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
8 Ophthalmology and Visual Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore

Acknowledgements
We would like to acknowledge Dr Victor Chan from the Chinese University of Hong Kong, Hong Kong, China; Dr Saima Hilal from National University of Singapore, Singapore; Dr Narayanaswamy Venketasubramanian from the Raffles Hospital, Singapore; and Dr M. Kamran Ikram from Erasmus Medical Centre, The Netherlands.

Contributors
CYC drafted the article. CYC, VM, PJF, ET, CPLHC, TYW and CPLHC were responsible for revising it critically for important intellectual content. All authors approved this version to be published.

Funding
CYC has received grant funding from the Health and Medical Research Fund, Hong Kong (Grant Number: 04153506) and Bright Focus Foundation (Reference Number: A20180935). VM has received grant funding from SEEDS Foundation. PJF has received grant support for this work from The Richard Desmond Charitable Foundation via Fight for Sight, London, UK (Grant code 1965), The International Glaucoma Association, Ashford, UK and The Alcon Research Institute, Fort Worth, Texas, USA. CPLHC has received grant funding from the National Medical Research Council Singapore (NMRC/CG/NHUS/2010 and NMRC/CG/013(2013)). ET has received grant funding from the EPSRC (MO59761/1) and the NIHR Global Health Research Unit “INSPIRED” (16/136/102). TYW has received grant funding from the National Medical Research Council Singapore (NMRC/STA/R1/016/2013 and NMRC/OLCG/001 c2017) and Duke-NUS Medical School (DUKE-NUS/RSF/2014/0001).

Competing interests
None declared.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs
Carol Y Cheung http://orcid.org/0000-0002-9672-1819
Christopher Chen http://orcid.org/0000-0002-1047-9225

REFERENCES
General neurology

Supplementary Section 1. Details of Retinal Imaging Technology for Specific Structures

1. Spectral-domain optical coherence tomography for imaging retinal neuronal and axonal layers

Optical coherence tomography (OCT) is an optical imaging technique that utilises a low-coherence light source near the infra-red spectrum to penetrate biological tissue and provides cross-sectional imaging of the retinal layered structure. Spectral-domain OCT (SD-OCT) employs a spectrometer to analyse the interference spectrum data from the back-scattered light which includes the retina depth information and generate axial measurements of the retina. Comparing with the earlier generation of OCT (time-domain OCT) which collected the signal as a function of time by moving a reference mirror mechanically, SD-OCT with the spectral analysis provides a higher resolution and higher speed for imaging the retinal layered structure. The recent development of swept-source OCT (SS-OCT), with a longer wavelength (>1µm) than SD-OCT and utilizing a frequency-swept light source, further enhances tissue penetration into the choroid and provides a faster scanning speed.

Assessment of inner retinal layers in greater details is possible after the development of SD-OCT, in particular the ganglion cell layer and inner-plexiform layer, which indicate cell bodies and dendrites of retinal ganglion cells (RGCs), respectively. Retinal layers (e.g. inner limiting membrane, nerve fibre layer, ganglion cell layer, inner plexiform layer and retinal pigment epithelium) are segmented automatically for different thickness and volume measurements (e.g. retinal nerve fibre layer (RNFL) thickness, ganglion cell-inner plexiform layer (GC-IPL) thickness, macular thickness and macular volume) at different locations by built-in segmentation algorithms in commercial OCT systems.
In addition to thickness measurement, built-in normative databases from healthy subjects are also provided for comparing the measured thickness or volume to age-matched data. The normative database uses a colour code to indicate the normal distribution percentiles (red: <1%, below normal limits; yellow: within 1% to 5%, suspect below normal; green: within 5%-95%, normal limits; light yellow: within 95%-99%, above normal limits; light red: >99%, above normal limits). For example, areas flagged in red indicate significant thickness reduction, compared with normative database.

2. Optical coherence tomography angiography for imaging retinal capillary networks

Optical coherence tomography-angiography (OCT-A) is based on mapping red blood cells movement over time from volumetric OCT scans. At each cross-sectional OCT image position, scan is repeated few times in order to detect and quantify the motion contrast. The degree of motion contrast is corresponding to angiographic flow, as the only expected motion in the retina is blood flow in vessels. Based on different image processing algorithms such as OCT Angiography Ratio Analysis (OCTARA), split-spectrum amplitude-decorrelation angiography (SSADA) and optical microangiography (OMAG) algorithm, OCT-angiography is able to penetrate into the retinal layers and image the various different capillary plexuses by selecting different en face slabs, thereby providing us the unique ability to reconstruct and view the retinal vasculature in a 3-dimensional fashion, as well as to visualize in isolation the individual retinal plexuses without intravenous dye injection (e.g. the superficial capillary plexus and deep capillary plexus).

It is noteworthy that the definition of “segmentation of retinal capillary plexuses” vary in different algorithms. For example, in the OCTARA, at macular region, the superficial capillary plexus default segmentation is defined as the region between the inner limiting membrane (ILM) + 2.6
μm to the inner plexiform layer (IPL)/inner nuclear layer (INL) border + 15.6 μm, while the deep capillary plexus default segmentation is defined as the region from the IPL/INL border + 15.6 μm to the IPL/INL border + 70.2 μm. In the SSASD, the superficial capillary plexus upper border is at 3 μm below ILM to the lower border at 15 μm below the IPL, while the deep capillary plexus spans from 15 μm below the IPL to 70 μm below the IPL. 

Quantification of capillary network from OCT-A to identify early and subtle microvascular changes objectively is one of the next important milestones for the application of OCT-A into clinical practice. Currently, several quantitative OCT-A measurements (e.g. vessel density, foveal avascular zone area and circularity, fractal dimension, vessel density index) have been defined and different automated and semi-automated algorithms developed to quantify the capillary networks. It is noted that projection artifacts from superficial blood vessels on the deeper layers (a fluctuating shadow cast by the flowing blood cells in the overlying retinal vessels projecting to the deeper layers) are common, which may lead to incorrect interpretations.

3. Enhanced depth imaging OCT for imaging choroidal vasculature

The choroid is the posterior part of the eyeball, which is sandwiched between the retina and the sclera, and is one of the most vascularized structures in the human body. Although SD-OCT can image the layered retina in details, imaging the choroid with SD-OCT is impeded by poor signal penetration beyond the heavily pigmented retinal pigment epithelium. With the introduction of enhanced depth imaging (EDI) technique of SD-OCT, the visualization of choroidal scleral interface is enhanced and imaging of choroidal vasculature has become possible. SS-OCT with a longer wavelength than SD-OCT, reducing the scatter reflection of the retinal pigment epithelium, also enables a better imaging of choroidal vasculature. The thickness and volume of the
choroid at different regions (e.g. subfovea, macula, peripapillary) can be subsequently measured by computer software. It is noteworthy that choroidal thickness is associated with several physiological variables (e.g. age, axial length of eyeball, intraocular pressure) in normal individuals. Choroidal vascularity index, defined as the ratio of vascular area to the total choroidal area, is recently proposed to quantify choroidal vascular alterations in a more reliable manner as it has lesser variability and influence by these factors.

4. Retinal vasculature analysis with retinal photography for imaging and quantifying retinal vasculature

The optical design of retinal photography with fundus camera is based on the principle of monocular indirect ophthalmoscopy, with the pupil used as both an entrance and exit for the fundus camera's illuminating and imaging light rays. With advancements in digital retinal photography and image processing technologies, quantitative retinal vasculature analysis from retinal photographs can be performed with computer software and standardized photographic protocols. Retinal Analysis (RA; University of Wisconsin, Madison, WI) and Integrative Vessel Analysis (IVAN; University of Wisconsin, Madison; WI) were widely used for measuring retinal arteriolar caliber and retinal venular caliber from retinal photographs in numerous large population-based studies. Retinal vessels, coursing through a specified area of a standardized grid (0.5–1.0 disc diameter from the disc margin), are measured. The revised Knudtson-Parr-Hubbard formula is widely used to summarize the retinal arteriolar and venular calibers of the large six arterioles and venules as central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) respectively. Subsequently, newer retinal geometric branching parameters were defined to quantify the optimal state of retinal vasculature in recent computer software systems (e.g. SIVA...
(Singapore I Vessel Assessment) software\textsuperscript{S103,S186} and VAMPIRE software (Vascular Assessment and Measurement Platform for Images of the REtina))\textsuperscript{S61} measured from a wider measured area, based on Murray’s principle that the branching pattern of vascular networks develops to minimize the energy required to maintain efficient blood flow.\textsuperscript{S53} It is noted that the current retinal vasculature analysis software tools are mainly semi-automated, and require manual adjustment and assessment usually by trained technicians to maximise the accuracy of the measurements.

5. Dynamic vessel analyzer for measuring the flicker-induced vasodilatory response

The principle of dynamic vessel analyzer (DVA) is based on dynamic reaction of retinal vessels to flickering light which stimulates activity of the neural retina and leads to retinal vessel dilation influenced by neurovascular coupling. In order to generate flickering light during DVA imaging, an optoelectric shutter is inserted in a retinal camera to produce a bright-to-dark contrast ratio of at least 25:1.\textsuperscript{S187} In each imaging cycle, retinal arteriolar and venular diameters are firstly measured in a certain time period for baseline measurement, followed by a stimulation with flickering light of the same wavelength for another time period, and then a non-flicker period. The responses to flickering light can be represented as an average increase in the retinal arteriolar and venular diameters during several cycles, and defined as the percentage increase relative to the baseline diameter size.\textsuperscript{S84}

6. Retinal oximetry for measuring retinal vessel oxygen saturation

Retinal oximeter, composed of an optical adapter and an image splitter fitted to a fundus camera, measures retinal vessel oxygen saturation based on acquisition of two images of the same area of the retinal fundus at two different wavelengths of light simultaneously. One of the two wavelengths
is sensitive to oxygen saturation (isosbestic wavelength of 570nm), i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation (non-isosbestic wavelength of 600nm) and is used to calibrate the light intensity. The oxygen saturation can therefore be estimated by comparing light absorption at oxygen sensitive wavelengths for assessing retinal oxygen metabolism. Nevertheless, the choroid may have a considerable role in oxygenating the inner retina under some circumstances (e.g. 100% oxygen breathing), but this is not accounted for in the current estimation of haemoglobin oxygen saturation.

7. Ultra-wide field retinal photography for imaging the retinal periphery

The technology of ultra-wide field retinal photography is based on confocal laser scanning microscopy combined with a concave ellipsoidal mirror, or white-light light-emitting diode illuminator, which enable a wide field of view to be imaged without the need for pupillary dilation. Ultra-wide field retinal photography has the ability to capture a much wider view of the retina (up to 200° horizontally or 82% of the retina) in a single image for assessment of peripheral lesions (e.g. drusen deposits, diabetic retinopathy), compared with conventional retinal photography (30° to 50° of the retina). The confocal laser scanning microscopy based system can allow for fundus autofluorescence imaging at the same time. It is noted that images from the confocal laser scanning microscopy can only produce pseudo-color images, but not true colour imaging like conventional fundus photography.

8. Fluorescence lifetime imaging ophthalmology for measuring and quantifying lifetimes of retinal fluorophore
Retinal fluorophores, including lipofuscin, advanced glycation end products, collagen, melanin, and elastin, absorb and emit light at specific wavelengths. Electrons in retinal fluorophores are excited by absorbing photons from a monochromatic light source (e.g. laser), thus moving to a higher level of energy. They return to their energy ground state by emitting photons of longer wavelengths than the exciting light. Fluorescence lifetime imaging ophthalmoscope (FLIO) is based on a commercial scanning laser ophthalmoscope which is equipped with an infrared camera for active eye tracking to correct for eye movements. During imaging, the excitation laser raster scans the retina in multiple periods, detects the emitted fluorophore and builds up a distribution histogram over time. The fluorescence lifetime describes the average time a single fluorophore remains in its electronically excited state after absorbing the energy of a photon and before returning to the ground state by emitting a photon. Every fluorophore is characterized by its own excitation and emission wavelength spectrum and exhibits an individual fluorescence lifetime. Therefore, it can produce quantitative images based on the lifetimes of the different retinal fluorophores.
Supplementary Table 1. Recent clinical studies of common primary age-related ocular diseases and Alzheimer’s diseases (AD) dementia.

<table>
<thead>
<tr>
<th>Clinical retinal diseases</th>
<th>Authors, years</th>
<th>Sample</th>
<th>Summary of results</th>
</tr>
</thead>
</table>
| Age-related macular degeneration (AMD) | Keenan et al. (2014) | Record linkage data of English National Health Service: an AMD cohort of 65,894 persons, a dementia cohort of 168,092 persons and a reference cohort of 7.7 million persons. | • For people with AMD: the rate ratio, comparing observed and expected cases of dementia in the AMD cohort with those of the reference cohort, was 0.91 (0.79, 1.04). The rate ratio for AD dementia after AMD was 0.86 (0.67, 1.08).  
• Persons with AMD not associated with incident dementia (RR: 0.91 [0.79, 1.04]) or AD dementia (RR: 0.86 [0.67–1.08]), compared with the reference cohort.  
• Persons with any forms of dementia (RR: 0.07 [0.04, 0.11]) and persons with AD dementia (RR: 0.04 [0.01,0.10]) were unlikely to develop AMD, compared with the reference cohort. |
| | Williams et al. (2014) | 258 AD dementia, and 322 healthy control subjects | • AMD grades not associated with AD dementia, compare with AMD Grade 0 (Grade 1: OR: 0.65 [0.4–1.1]; Grade 2: OR: 1.00 [0.5–1.9]; Grade 3: OR: 1.38 [0.6–3.2]). |
| | Tsai et al. (2015) | Claims data of the Taiwan National Health Insurance Research Database: an AMD cohort of 4,993 person (4,453 non-exudative AMD and 540 exudative AMD) and an age-gender-matched reference cohort of 24,965 persons. | • 5.9% and 5.2% persons were diagnosed with AD or senile dementia during a mean follow-up period of 4.4 years in the AMD cohort and the control cohort, respectively.  
• Persons with AMD were more likely to develop AD dementia or senile dementia (HR: 1.44 [1.26, 1.64]), compared with controls.  
• The association was stronger in non-exudative AMD (HR:1.44 [1.26, 1.65]). |
| | Lee et al. (2018) | 3,877 participants with dementia-free at enrollment from the Adult Changes in Thought Study | • 347 (9%) had an AMD diagnosis at enrollment, and 689 (18%) developed AMD  
• Established AMD (>5 years) associated with incident AD dementia (HR: 1.50 [1.25, 1.8]). |
| Diabetic retinopathy (DR) | | | |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Findings</th>
</tr>
</thead>
</table>
| Lee et al. (2018)                           | 3,877 participants with dementia-free at enrollment from the Adult Changes in Thought Study | • 136 (4%) had a DR diagnosis at enrollment, and 112 (3%) developed DR.  
• Both recent DR (within 5 years) (HR: 1.67 [1.01, 2.74]) and established DR (>5 years) (HR: 1.50 [1.05, 2.15]) associated with incident AD dementia. |
| **Glaucoma**                                |                                                               |                                                                                                                                           |
| Lin et al. (2014)                           | Claims data of the Taiwan National Health Insurance Research Database: a primary open-angle glaucoma (POAG) cohort of 3,979 persons and a non-glaucoma cohort of 15,916 persons | • The incidence rates of AD dementia among the patients with and without POAG were 2.85 (2.19, 3.70) and 1.98 (1.68, 2.31) per 1000 person-years, respectively.  
• Persons with POAG were more likely to develop AD dementia (HR: 1.40 [1.03, 1.90]), but not Parkinson disease (HR: 0.98 [0.77, 1.24]), over 8 years, compared with non-glaucoma cohort. |
| Keenan et al. (2015)                        | Record linkage data of English National Health Service: a POAG cohort of 87,658 persons, an AD dementia cohort of 251,703 persons, a vascular dementia cohort of 217,302 persons and a reference cohort of >2.5 million persons. | • For people with POAG, there was no significant association with AD: the rate ratio, comparing the POAG cohort with the reference cohort, was 1.01 (0.96, 1.06). The rate ratio for AD dementia after AMD was 0.86 (0.67, 1.08).  
• Persons with POAG not associated with incident AD dementia (RR:1.01 [0.96, 1.06]), but likely to develop vascular dementia (RR: 1.10 [1.05 to 1.16]), compared with the reference cohort.  
• Persons with AD dementia (RR: 0.28 [0.24 to 0.31]) or vascular dementia (RR: 0.32 [0.28 to 0.37]), were unlikely to develop POAG, compared with the reference cohort. |
| Lee et al. (2018)                           | 3,877 participants from the Adult Changes in Thought Study    | • 404 (10%) had a glaucoma diagnosis at enrollment, and 290 (7%) developed glaucoma.  
• Recent glaucoma (within 5 years) associated with incident AD dementia (HR: 1.46 [1.08, 1.91]). |
**Supplementary Table 2.** Recent clinical studies of spectrum of Alzheimer’s diseases (AD) (AD dementia, mild cognitive impairment (AD MCI), preclinical AD), and retinal imaging measures, as defined from spectral-domain optical coherence tomography (SD-OCT), OCT-angiography, enhanced depth imaging (EDI) with OCT and retinal photography. It is noted that the definition of AD varies in the existing literature: not all publications have included AD biomarkers for their AD diagnosis. The evolution in definition and diagnostic criteria of AD and other dementias may account for some of the variations and differences seen between studies discussed in this review.

<table>
<thead>
<tr>
<th>Authors, years</th>
<th>Sample</th>
<th>Imaging measure</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cross-sectional SD-OCT studies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Larrosa et al. (2014) | 151 AD dementia, and 61 age-matched normal control subjects | A selective combination of peripapillary RNFL and macular thicknesses using linear discriminant function | • Reduced peripapillary RNFL thickness using linear discriminant function in AD dementia (all \( p < 0.001 \)), compared with controls.  
• The largest AUROCs were 0.967 for the Spectralis RNFL based linear discriminant function and 0.830 for the Cirrus RNFL based linear discriminant function. |
| Polo et al. (2014) | 75 AD dementia, and 75 age-matched normal control subjects | Peripapillary RNFL and macular thickness | • Reduced peripapillary RNFL in superior (113.59µm vs. 118.58µm, \( p = 0.006 \)) and inferior (121.96 µm vs. 127.97 µm, \( p = 0.018 \)) quadrants, and macular thicknesses (all \( p \leq 0.009 \), except measurement at fovea \( p = 0.115 \)) in AD dementia, compared with controls.  
• Reduced peripapillary RNFL thickness in superior quadrant in AD dementia (109.1µm vs. 111.1µm, \( p = 0.039 \)), compared with controls.  
• No difference in macular GC-IPL and peripapillary RNFL thicknesses between MCI and AD dementia. |
| Cheung et al. (2015) | 100 AD dementia, 41 MCI, and 123 normal control subjects | Macular GC-IPL and Peripapillary RNFL thicknesses | • Reduced macular GC-IPL thickness in MCI (all \( p \leq 0.049 \), except measurement at superior \( p = 0.064 \), inferonasal \( p = 0.051 \) and supertemporal \( p = 0.359 \) sectors) in AD dementia (all \( p \leq 0.031 \)), compared with controls.  
• Reduced peripapillary RNFL thickness in superior quadrant in AD dementia (109.1µm vs. 111.1µm, \( p = 0.039 \)), compared with controls.  
• No difference in macular GC-IPL and peripapillary RNFL thicknesses between MCI and AD dementia. |
| Ferrari et al. (2016) | 39 AD dementia, 17 frontotemporal dementia (FTD), 27 MCI and 49 normal control subjects | Peripapillary RNFL and GC-IPL thicknesses | • Reduced peripapillary RNFL and GC-IPL thicknesses in AD dementia (mild AD: RNFL=94.55 µm, GC-IPL=57.52µm; moderate AD: RNFL=91.33µm, GC-IPL=50.07µm), FTD (RNFL=87.47µm, GC-IPL=51.83µm) and MCI (RNFL=92.79µm, |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Measurements</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garcia-Martin et al. (2016)</td>
<td>150 AD dementia and 75 age-gender-matched normal control subjects</td>
<td>Macular RNFL, GCL, IPL, INL, OPL, ONL, RPE layer thicknesses</td>
<td>Reduced macular RNFL (6.11 vs. 6.22), GCL (6.27 vs. 6.45), INL (6.56 vs. 6.71) and ONL (6.56 vs. 6.71) thicknesses in AD dementia (p&lt;0.05), compared with controls. Reduced RNFL (p=0.018), GCL (p=0.009) and INL (p=0.006) thicknesses correlated with disease duration in AD dementia.</td>
</tr>
<tr>
<td>Snyder et al. (2016)</td>
<td>10 Aβ-positive and 53 Aβ-negative subjects at high-risk for AD (self-reported first-degree family history of the disease, and self-identification of subjective memory concerns)</td>
<td>Peripapillary RNFL and macular RNFL, GCL, IPL, INL, OPL, and ONL thicknesses</td>
<td>Increased IPL in Aβ-positive group (p=0.029), compared with Aβ-negative group (0.371µm vs. 0.354 µm³).</td>
</tr>
<tr>
<td>Cunha et al. (2017)</td>
<td>50 mild AD dementia and 152 normal control subjects</td>
<td>Peripapillary RNFL and macular thicknesses</td>
<td>Reduced peripapillary RNFL thickness in superiotemporal sector (p&lt;0.05) and macular thicknesses in pericentral (p=0.001) and peripheral superior (p&lt;0.001) sectors in AD dementia, compared with controls.</td>
</tr>
<tr>
<td>Lad et al. (2018)</td>
<td>15 AD dementia, 15 MCI and 18 normal control subjects</td>
<td>Peripapillary RNFL and macular RNFL and GC-IPL thicknesses</td>
<td>No significant associations observed. Using a multivariate regression model with quasi-least squares, there are areas of thickening of macular GC-IPL and RNFL in subjects with AD dementia and MCI, compared with controls.</td>
</tr>
<tr>
<td>O’Bryhim et al. (2018)</td>
<td>14 preclinical AD (Aβ-positive from PET or CSF but not dementia) and 16 normal control subjects</td>
<td>Inner, outer, and total foveal thicknesses</td>
<td>Reduced inner foveal thickness (66.0µm vs. 75.4µm, p=0.03) in preclinical AD, compared with controls.</td>
</tr>
<tr>
<td>Sanchez et al. (2018)</td>
<td>324 AD dementia, 192 MCI and 414 normal control subjects</td>
<td>Peripapillary RNFL thickness</td>
<td>No difference in peripapillary RNFL thickness among the groups.</td>
</tr>
<tr>
<td>den Haan et al. (2019)</td>
<td>57 AD dementia and 85 normal control subjects</td>
<td>Peripapillary RNFL, total macular and macular RNFL, GCL and IPL thicknesses</td>
<td>No difference in peripapillary RNFL, total macular and macular RNFL, GCL and IPL thicknesses among the groups.</td>
</tr>
</tbody>
</table>
Tao et al. (2019)\textsuperscript{26}  73 AD dementia, 51 MCI and 67 normal control subjects  Peripapillary RNFL and macular GCC thicknesses  • Reduced peripapillary RNFL (97.99µm vs. 98.35µm vs. 107.19µm) and macular GCC thicknesses (94.16µm vs. 94.1µm vs. 99.64µm) in AD dementia and MCI (all p<0.05), compared with controls.  • No difference in peripapillary RNFL and macular GCC thicknesses between MCI and AD dementia.

Asanad et al. (2020)\textsuperscript{5198}  27 preclinical AD (pathological Aβ42/Tau ratio from CSF but not dementia) and 16 normal control subjects  Peripapillary RNFL, macular GC-IPL and macular thicknesses  • Reduced peripapillary RNFL thicknesses in preclinical AD dementia (83.46µm vs. 93.27µm, p=0.0009), compared with controls.

McCann et al. (2020)\textsuperscript{5199}  3,221 subjects from the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA)  Peripapillary RNFL thickness  • Reduced associated with AD (self-reported) in the age-adjusted and sex-adjusted model.

**Prospective SD-OCT studies**

Shi et al. (2014)\textsuperscript{29}  20 MCI and 58 normal control subjects  Peripapillary RNFL thickness  • The reduction in peripapillary RNFL at inferior region in the converted participants was greater than that in stable participants (−11.0µm vs 0.4µm, p = 0.009) over a 25-month follow-up.

Trebbastoni et al. (2016)\textsuperscript{31}  36 AD dementia and 36 age-matched normal control subjects  Peripapillary RNFL thickness  • Changes in peripapillary RNFL thickness in inferior region associated with worsening cognitive scores (ADAS-Cog scores change: r = −0.35, p = 0.02; CDR scores change: r = −0.39, p = 0.008) over a 12-month follow-up.

Choi et al. (2016)\textsuperscript{30}  42 AD dementia, 26 MCI and 66 normal control subjects  Peripapillary RNFL, macular GC-IPL and macular thicknesses  • Reduced average (Beta=−0.150, p=0.006) and sectoral GC-IPL (all p<0.05) and macular (Beta=−1.700, p=0.02) thicknesses at baseline associated with progression of AD dementia and MCI over a 2-year follow-up.

Mutlu et al. (2018)\textsuperscript{27}  3,289 subjects from the Rotterdam Study  Peripapillary RNFL and macular GC-IPL thicknesses  • Reduced GC-IPL (OR: 1.03 [1.00, 1.09]) associated with prevalent dementia.  • Reduced RNFL (HR: 1.02 [1.01, 1.04]) associated with incident of dementia, including AD dementia (HR: 1.02 [1.01, 1.04]).
<table>
<thead>
<tr>
<th>Study</th>
<th>Group</th>
<th>Outcome Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Santos et al. (2018)</td>
<td>15 preclinical AD and 41 normal control subjects</td>
<td>Peripapillary RNFL and macular RNFL, GCL, IPL, INL, OPL, and ONL thicknesses.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> A larger reduction in macular RNFL (-0.032mm³ vs. -0.019mm³, p=0.050), ONL (-0.029mm³ vs. -0.007mm³, p=0.026), and IPL (-0.014mm³ vs. -0.006mm³, p=0.020) volumes, in preclinical AD over a 27-month follow-up, compared with controls.</td>
</tr>
<tr>
<td>OCT-angiography studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jiang et al. (2018)</td>
<td>12 AD dementia, 19 MCI and 21 age-matched normal control subjects</td>
<td>Vessel density of retinal vascular network, superficial capillary plexus, and deep capillary plexus.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> Decreased density of retinal vascular network, superficial vascular plexus, and deep vascular plexus in AD dementia (p&lt;0.05), compared with controls.</td>
</tr>
<tr>
<td>Bulut et al. (2018)</td>
<td>26 AD dementia and 26 age-gender matched normal control subjects</td>
<td>Vessel density and foveal avascular zone area of superficial capillary plexus.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> Decreased density (45.40% vs. 48.67%, p=0.002) and enlarged foveal avascular zone area (0.47mm² vs. 0.33mm², p=0.001) of superficial capillary plexus in AD dementia, compared with controls.</td>
</tr>
<tr>
<td>O’Bryhim et al. (2018)</td>
<td>14 preclinical AD (Aβ-positive from PET or CSF but not dementia) and 16 normal control subjects</td>
<td>Foveal avascular zone area.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> Enlarged foveal avascular zone area (0.364mm² vs. 0.275mm², p=0.002) in preclinical AD, compared with controls, with AUROC of 0.8007.</td>
</tr>
<tr>
<td>Lahme et al. (2018)</td>
<td>36 AD dementia and 27 normal control subjects</td>
<td>Foveal avascular zone area and vessel density of superficial capillary plexus, deep capillary plexus and radial peripapillary capillary.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> Decreased vessel density of superficial capillary plexus (48.77% vs. 51.64%, p=0.001) and radial peripapillary capillary (53.07% vs. 55.39%, p=0.015) in AD dementia, compared with controls.</td>
</tr>
<tr>
<td>Querques et al. (2019)</td>
<td>12 AD dementia, 12 MCI, and 32 age-gender matched normal control subjects</td>
<td>Vessel density of superficial capillary plexus and deep capillary plexus.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> No differences in all the measures.</td>
</tr>
<tr>
<td>den Haan et al. (2019)</td>
<td>48 AD dementia, and 38 normal control subjects</td>
<td>Vessel density and foveal avascular zone area</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> No differences in all the measures.</td>
</tr>
<tr>
<td>Zhang et al. (2019)</td>
<td>16 early AD or amnestic MCI, and 16 normal control subjects</td>
<td>Vessel density and vessel length density of superficial capillary plexus, radial peripapillary capillary and peripapillary superficial vascular plexus. Adjusted</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>•</strong> Decreased vessel density (40.67% vs. 44.5%, p=0.028) and adjusted flow index (0.376 vs. 0.407, p=0.047) of superficial capillary plexus in early AD or amnestic MCI, compared with controls.</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Methods</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>van de Kreeke et al. (2019)</td>
<td>13 preclinical AD (Aβ-positive from PET but not dementia) and 111 normal control subjects</td>
<td>Flow index of superficial capillary plexus.</td>
</tr>
<tr>
<td>Zabel et al. (2019)</td>
<td>27 AD dementia, 27 open-angle glaucoma and 27 normal control subjects</td>
<td>Foveal avascular zone area and vessel density of superficial capillary plexus, deep capillary plexus and radial peripapillary capillary.</td>
</tr>
<tr>
<td>Lee et al. (2020)</td>
<td>29 AD-related cognitive impairment, 25 subcortical vascular cognitive impairment and 15 normal control subjects</td>
<td>Vessel density of radial peripapillary capillary.</td>
</tr>
<tr>
<td>OCT with EDI studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gharbiya et al. (2014)</td>
<td>21 mild to moderate AD dementia and 21 age-matched normal control subjects</td>
<td>Choroidal thickness</td>
</tr>
<tr>
<td>Bayhan et al. (2015)</td>
<td>31 AD dementia and 30 age-matched normal control subjects</td>
<td>Choroidal thickness</td>
</tr>
<tr>
<td>Trebbastoni et al. (2017)</td>
<td>39 AD dementia and 39 normal control subjects</td>
<td>Choroidal thickness</td>
</tr>
<tr>
<td>Bulut et al. (2018)</td>
<td>26 AD dementia and 26 age-gender matched normal control subjects</td>
<td>Choroidal thickness</td>
</tr>
<tr>
<td>Retinal photography studies</td>
<td>Participants</td>
<td>Measurements</td>
</tr>
<tr>
<td>----------------------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
</tbody>
</table>
| Frost et al. (2013)⁹⁹     | 25 AD dementia, and 123 age-matched control subjects | CRAE, CRVE, FD, tortuosity, bifurcation | • Decreased CRAE (122.9µm vs. 129.1µm, p=0.01), CRVE (169.7µm vs. 182.7µm, p<0.001), arteriolar FD (1.201 vs. 1.235, p=0.008), venular FD (1.171 vs. 1.210, p<0.001), venular tortuosity (6.953x10⁻⁵ vs. 7.660x10⁻⁵, p=0.024) and venular branching coefficient (1.347 vs. 1.253, p=0.019) in AD dementia, compared with controls.  
  • Increased venular branching asymmetry factor (p=0.01) and arteriolar length-to-diameter ratio (p=0.02) in preclinical AD, compared with Aβ-negative subjects. |
| Cheung et al. (2014)⁴⁰   | 136 AD dementia, and 290 age-matched control subjects | CRAE, CRVE, FD, tortuosity, bifurcation | • Decreased CRVE (OR 2.01 [1.27, 3.19]), arteriolar (OR 1.35 [1.08, 1.68]) and venular (OR 1.47 [1.17, 1.84]) FDs, and increased arteriolar (OR 1.80 [1.40, 2.31]) and venular (OR 1.94 [1.48, 2.53]) tortuosity associated with AD dementia. |
| Williams et al. (2015)⁴¹  | 213 AD dementia, and 294 age-matched control subjects | CRAE, CRVE, FD, tortuosity, bifurcation | • Decreased total FD (OR 0.77 [0.62, 0.97]) and arteriolar tortuosity (OR 0.78 [0.63, 0.97]) associated with AD dementia. |
| den Haan et al. (2019)⁵⁷² | 48 AD dementia, and 38 normal control subjects | CRAE, CRVE, FD, tortuosity | • No differences in all the measures |

Aβ=amyloid-beta; AD=Alzheimer’s disease; AUROC=area under receiver operating characteristic curve; CRAE=central retinal artery equivalent; CRVE=central retinal vein equivalent; CSF=cerebrospinal fluid; EDI=enhanced depth imaging; FD=fractal dimension; GCC=ganglion cell complex; GC-IPL=ganglion cell-inner plexiform layer; GCL= ganglion cell layer; HR=hazard ratio; INL=inner nuclear layer; IPL=inner plexiform layer; MCI=mild cognitive impairment; OPL=outer plexiform layer; ONL=outer nuclear layer; OR=odds ratio; RNFL=retinal nerve fiber layer; RPE=retinal pigment epithelium; OCT=optical coherence tomography; PET=positron emission tomography.
**Supplementary Table 3.** A proposed framework of research using retinal imaging technology as a source of biomarkers for Alzheimer’s disease (AD).

<table>
<thead>
<tr>
<th>Items in the Framework</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Study should be designed and conducted with a specific clinical purpose.</td>
<td>Can spectral-domain (SD-OCT) be used as a screening tool to identify asymptomatic individuals who are more likely to have AD in community, neurology clinics, eye clinics or optical shops?</td>
</tr>
<tr>
<td>2. Diagnosis of AD should be defined in a consistent manner with the latest available criteria.</td>
<td>AD should be defined by biomarkers of amyloid-β deposition, pathologic tau, and neurodegeneration.</td>
</tr>
<tr>
<td>3. Standard statistical measures of accuracy of biomarkers should be reported.</td>
<td>The sensitivity, specificity, false-positive and false-negative rates of SD-OCT measures should be reported, using the above as a reference standard.</td>
</tr>
<tr>
<td>4. Studies should be designed carefully to take into account many age-related ocular conditions.</td>
<td>How do different ocular conditions (e.g. glaucoma, age-related macular degeneration and elongated eyeball) manifest on SD-OCT? How do these ocular conditions be considered in the analysis and interpretation?</td>
</tr>
<tr>
<td>5. The reproducibility of the retinal imaging measures should be determined.</td>
<td>What are the intra-visit repeatability and inter-visit reproducibility of SD-OCT measures?</td>
</tr>
<tr>
<td>6. The incremental benefit and cost-effectiveness of retinal imaging as well as acceptability to patients in different settings should be evaluated.</td>
<td>What are the benefits to screen AD using SD-OCT in community, neurology clinics, eye clinics or optical shops?</td>
</tr>
</tbody>
</table>
**Supplementary Figure 1.** Image processing steps (e.g. image denoising, binarization, skeletonization) to quantify the retinal capillary networks (superficial capillary plexus, deep capillary plexus and radial peripapillary capillary plexus) from optical coherence tomography angiography (OCT-A) images in a subject with Alzheimer disease dementia.
Supplementary Figure 2. An example of presence of drusen deposits in the peripheral retina (appear as yellow deposits under the retina, indicated by white arrows) imaged by ultra-widefield scanning laser ophthalmoscopy (Daytona, Optos, Dunfermline, UK) in a 77-year-old subject with Alzheimer’s disease dementia (global clinical dementia rating score of 1). Except presence of drusen deposits in the peripheral retina, no other retinal disorders were observed in this subject. These peripheral drusen deposits are not present in healthy individuals without eye diseases.
Supplementary Figure 3. A proposed pathway of screening Alzheimer’s disease (AD) using retinal imaging assisted by artificial intelligence (AI). By providing a simple 2-tier risk stratification output, the AI algorithm could assist physicians to identify asymptomatic individuals who are more likely to have AD in different settings (e.g. community-based, eye clinic-based, general or specialized clinics). The high-risk group can then benefit from subsequent confirmatory investigations (e.g. PET imaging and cerebrospinal fluid tests), implementation of potential preventive therapies or recruitment into clinical trials.
Supplementary References


